Are some progestins genotoxic liver carcinogens?

Mutation Research - Reviews in Mutation Research

Volumn 512, Issue 2-3, 2002, Pages 155-163

  Brambilla, Giovanni ^a   Martelli, Antonietta ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

17 Hydroxy 3 oxopregna 4,6 diene derivatives; Liver specific genotoxic activity; Progestins

Indexed keywords

CANRENOATE POTASSIUM; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; ESTROGEN; GESTAGEN; MEGESTROL ACETATE; ORAL CONTRACEPTIVE AGENT;

BREAST CARCINOMA; CARCINOGENIC ACTIVITY; CARCINOGENICITY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG ACTIVATION; DRUG HALF LIFE; ENDOMETRIUM CARCINOMA; GENOTOXICITY; HUMAN; HYPOTHESIS; LIVER CELL CARCINOMA; LIVER TOXICITY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; STRUCTURE ACTIVITY RELATION;

EID: 0036900067     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(02)00047-9     Document Type: Review

References (50)

1. D.S. Loose-Mitchell, G.M. Stancel, Estrogens and progestins, in: J.G. Hardman, L.E. Limbird, A. Goodman, Gilman (Eds.), The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill, New York, 2001, pp. 1597-1634.
2. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, Hormonal Contraception and Post-Menopausal Hormonal Therapy, Vol. 72, IARC, Lyon, France, 1999.
3. Lang R., Reimann U. Non-mutagenicity of some sex hormones in the Ames Salmonella/microsome mutagenicity test. Mutat. Res. 67:1979;361-365.
4. Lang R., Reimann R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutation using the Ames Salmonella/microsome test and the HGPRT test in V79 cells. Environ. Mol. Mutagen. 21:1993;272-304.
5. Reimann R., Kalweit S., Lang R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. II. Communication: examination for the induction of cytogenetic damage using the chromosomal aberration assay on human lymphocytes in vitro and the mouse bone marrow micronucleus test in vivo. Environ. Mol. Mutagen. 28(2):1996;133-144.
6. Schuppler J., Günzel P. Liver tumors and steroid hormones in rats and mice. Arch. Toxicol. 2:1979;181-195.
7. Schulte-Hermann R., Ohde G., Schuppler J., Timmermann-Trosiener I. Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds, and nafenopin. Cancer Res. 41:1981;2556-2562.
8. Schulte-Hermann R., Timmermann-Trosiener I., Schuppler J. Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by non-mutagenic compounds. Cancer Res. 43:1983;839-844.
9. Ochs H., Düsterberg B., Günzel P., Schulte-Hermann R. Effect of tumor promoting contraceptive steroids on growth and drug metabolizing enzymes in rat liver. Cancer Res. 46:1986;1224-1232.
10. Schulte-Hermann R., Ochs H., Bursh W., Parzefall W. Quantitative structure-activity studies on effects of 16 different steroids on growth and mono-oxygenases of rat liver. Cancer Res. 48:1988;2462-2468.
11. Topinka J., Andrae U., Schwarz L.R., Wolff T. Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. Carcinogenesis. 14:1993;423-427.
12. Werner S., Topinka J., Wolff T., Schwarz L.R. Accumulation and persistence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver. Carcinogenesis. 16:1995;2369-2372.
13. Topinka J., Binkova B., Schwarz L.R., Wolff T. Cyproterone acetate is an integral part of hepatic DNA adducts induced by this steroidal drug. Carcinogenesis. 17:1996;167-169.
14. Werner S., Kunz S., Beckurts T., Heidecke C.-D., Wolff T., Schwarz L.R. Formation of DNA adducts by cyproterone acetate and some structural analogues in primary cultures of human hepatocytes. Mutat. Res. 395:1997;179-187.
15. 32P -post-labeling technique Pharmacol. Toxicol. 78:1996;214-223.
16. Feser W., Kerdar R.S., Bauman A., Körber J., Blode H., Kuhnz W. DNA adduct formation of selected sex steroids in human liver slices in vitro. Toxicol. In Vitro. 12:1998;353-364.
17. Neumann I., Thierau D., Andrae U., Greim H., Schwarz L.R. Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in γ-glutamyltranspeptidase-positive cells. Carcinogenesis. 13:1992;373-378.
18. Martelli A., Mattioli F., Fazio S., Andrae U., Brambilla G. DNA repair synthesis and DNA fragmentation in primary cultures of human and rat hepatocytes exposed to cyproterone acetate. Carcinogenesis. 16:1995;1265-1269.
19. Martelli A., Mattioli F., Ghia M., Mereto E., Brambilla G. Comparative study of DNA repair induced by cyproterone acetate, chlormadinone acetate and megestrol acetate in primary cultures of human and rat hepatocytes. Carcinogenesis. 17:1996;1153-1156.
20. Kasper P., Mueller L. Time-related induction of DNA repair synthesis in rat hepatocytes following in vivo treatment with cyproterone acetate. Carcinogenesis. 17:1996;2271-2274.
21. Martelli A., Brambilla Campart G., Ghia M., Allavena A., Mereto E., Brambilla G. Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate or megestrol acetate. Carcinogenesis. 17:1996;551-554.
22. Deml E., Schwarz L.R., Oesterle D. Initiation of enzyme-altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay. Carcinogenesis. 14:1993;1229-1231.
23. Krebs O., Schäfer B., Wolff T., Oesterle D., Denil E., Sund M., Favor J. The DNA damaging drug cyproterone acetate causes gene mutation and induces glutathione-S-tranferase P in the liver of female Big Blue™ transgenic F344 rats. Carcinogenesis. 19:1998;241-245.
24. Kerdar R.S., Baumann A., Brudny-Klöppel M., Biere H., Blode H., Kuhnz W. Identification of 3α-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro. Carcinogenesis. 16:1995;1835-1841.
25. Werner S., Kunz S., Wolff T., Schwarz L.R. Steroidal drug cyproterone acetate is activated to DNA-binding metabolites by sulfonation. Cancer Res. 56:1996;4391-4397.
26. Homma H., Nakagome I., Kamakura M., Hirota M., Takahashi M., Matsui M. Studies on rat hepatic hydroxysteroid sulfotransferase-immunochemistry, development and pI variants. Chem. Biol. Interact. 92:1994;15-24.
27. Aksoy I.A., Sochorova V., Weinshilboum R. Human liver dehydroepiandrosterone sulfotransferase: nature and extent of individual variation. Clin. Pharmacol. Ther. 54:1993;498-506.
28. Topinka J., Binkova B., Zhu H.K., Andrae U., Neumann I., Schwarz L.R., Werner S., Wolff T. DNA damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. Carcinogenesis. 16:1995;1483-1487.
29. Cook C.S., Hauswald C.L., Schoenhard G.L., Piper C.E., Patel A., Radzialowski F.M., Hribar J.D., Aksamit W., Finnegan P., Bible R.H., Oppermann J.A. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate. Arch. Toxicol. 61:1988;201-212.
30. Cook C.S., Hauswald C., Oppermann J.A., Schoenhard G.L. Involvment of cytochrome P-450IIIA in metabolism of potassium canrenoate to an epoxide: mechanism of inhibition of the epoxide formation by spironolactone and its sulfur-containing metabolite. J. Pharmacol. Exp. Ther. 266:1993;1-7.
31. Martelli A., Mattioli F., Carrozzino R., Ferraris E., Marchese M., Angiola M., Brambilla G. Genotoxicity testing of potassium canrenoate in cultured rat and human cells. Mutagenesis. 14:1999;463-472.
32. Martelli A., Carrozzino R., Mattioli F., Bucci G., Lamarino G., Brambilla G. DNA damage in tissues of rats treated with potassium canrenoate. Toxicology. 171:2002;95-103.
33. Kasper P., Tegethoff K., Mueller L. In vitro mutagenicity studies on cyproterone acetate using female rat hepatocytes for metabolic activation and as indicator cells. Carcinogenesis. 16:1995;2309-2314.
34. Martelli A., Mereto E., Ghia M., Orsi P., Allavena A., De Pascalis C.R., Brambilla G. Induction of micronuclei and of enzyme altered foci in the liver of female rats exposed to progesterone and three synthetic progestins. Mutat. Res. 419:1998;33-41.
35. Kuhnz W., Staks T., Jütting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraception. 48:1993;557-575.
36. Schleicher E., Täuber U., Louton T., Schunack W. Tissue distribution of sex steroids: concentration of 17β-oestradiol and cyproterone acetate in selected organs of female Wistar rats. Pharmacol. Toxicol. 82:1998;34-39.
37. Ramsay L., Shelton J., Harrison I., Tidd M., Asbury M. Spironolactone and potassium canrenoate in normal man. Clin. Pharmacol. Ther. 20:1976;167-177.
38. Kirsch-Volders M., Aardema M., Elkajouji A. Concepts of threshold in mutagenesis and carcinogenesis. Mutat. Res. 464:2000;3-11.
39. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, Vols. 1-42, Suppl. 7, IARC, Lyon, France, 1987.
40. Collaborative MILTS Project Team, Oral contraceptives and liver cancer, Contraception 56 (1997) 275-284.
41. Ohri S.K., Caer J.A.R., Keane P.F. Hepatocellular carcinoma and treatment with cyproterone acetate. Br. Med. Urol. 67:1991;213-221.
42. Katan J., Spatz A., Culine S.et al. Hepatocellular carcinoma during hormone therapy for prostatic cancer. Am. J. Clin. Oncol. Cancer Clin. Ther. 17:1994;390-392.
43. S. Watanabe, S. Yamasaki, A. Tanae, I. Hibi, T. Homme, Ad hoc Committee on Androcur Use, Three cases of hepatocellular carcinoma among cyproterone users, Lancet 344 (1994) 1567-1568.
44. Watanabe S., Cui Y., Tanae A., Tanaka T., Fujimoto M., Matsuo Y., Tachibana K., Yamasaki S. Follow-up study of children with precocious puberty treated with cyproterone acetate. J. Epidemiol. 7:1997;173-178.
45. Rüdiger T., Beckmann J., Queiber W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinylestradiol. Lancet. 345:1995;452-453.
46. Kasper P. Cyproterone acetate: a genotoxic carcinogen? Pharmacol. Toxicol. 88:2001;223-231.
47. Stenchever M.A., Jarvis J.A., Kreyer N.K. Effect of selected estrogens and progestins on human chromosomes in vitro. Obstet. Gynecol. 34:1969;249-252.
48. Dayan J., Crajer M.C., Bertozzi S., Lefrancois S. Application of the Salmonella typhimurium/microsome test to the study of 25 drugs belonging to 5 chemical series. Mutat. Res. 77:1980;301-306.
49. Blakey D.C., White I.N.H. Unscheduled DNA synthesis caused by norethindrone and related contraceptive steroids in short-term male rat hepatocyte cultures. Carcinogenesis. 6:1985;1201-1205.
50. White I.N.H., Green M.L., Legg R.F. Fluorescence-activated sorting of rat hepatocytes based on their mixed function oxidase activities towards diethoxyfluorescein. Biochem. J. 247:1987;23-28.